Accelerated approval is the proper path for UniQure
The case was made that UniQure's therapy meets the standard for an FDA accelerated approval, which is designed for situations with a strong biomarker signal but where definitive clinical endpoint data is still accumulating.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.